~~<i id='F81E1FE0E1'><strike id='F81E1FE0E1'><tt id='F81E1FE0E1'><pre id='F81E1FE0E1'></pre></tt></strike></i>~~

Home» explore» hotspot

hotspot

author：knowledge 2025-09-30 20:16:05 Page View：94826

Venture capitalist Alexis Borisy Vanessa Leroy for STAT

EQRx is done, sold for its cash.

The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Alabama hospital puts IVF treatments on hold
Next article： Sports medicine is finally prioritizing gender equality

focus

Wildfire smoke exposes gaps in outdoor worker protections

ApersonwaitingforthesubwaywearsafilteredmaskassmokyhazefromwildfiresinCanadablanketsaneighborhoodinN

Readout LOUD podcast: Humira legacy, AbbVie CEO's retirement

WhatdoCEOsowetheworld?DidHumirabreakthesystem?AndcanyouCRISPRafetus?Wecoverallthatandmorethisweekon“

Anesthesiologist group: stop taking Ozempic before surgery

EspeciallyinthefirstweeksoftakingdrugslikeOzempic,foodstayslongerinthestomach—aprobleminsurgeries.Ad

With competition flaring, obesity drug hits goal in liver disease study

AdobeLONDON—AdrugindevelopmentasaweightlosstreatmentsucceededinaPhase2studyinaseriouslivercondition,

WSS

hotspot

hotspot

comprehensive

focus

With competition flaring, obesity drug hits goal in liver disease study